Human IGFBP-3 Quantikine ELISA Kit

(16 citations)   
  • Assay Type
    Solid Phase Sandwich ELISA
  • Format
    96-well strip plate
  • Assay Length
    4.5 hours
  • Sample Type & Volume Required Per Well
    Cell Culture Supernates (100 uL), Serum (10 uL), EDTA Plasma (10 uL), Heparin Plasma (10 uL)
  • Sensitivity
    0.14 ng/mL
  • Assay Range
    0.8 - 50 ng/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
  • Specificity
    Natural and recombinant human IGFBP-3
  • Cross-reactivity
    < 0.5% cross-reactivity observed with available related molecules.Cross-species reactivity not tested.
  • Interference
    No significant interference observed with available related molecules.
Control Available
QC23, Quantikine Immunoassay Control Group 8 - Please Inquire
Product Summary
The Quantikine Human IGFBP-3 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human IGFBP-3 in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human IGFBP-3 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human IGFBP-3 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human IGFBP-3.

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.
Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma
Intra-Assay Precision Inter-Assay Precision
Standard Deviation0.20.640.710.220.762.27


The recovery of IGFBP-3 spiked to three different levels throughout the range of the assay was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 94 89-99
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of IGFBP-3 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human IGFBP-3 Quantikine ELISA Kit
Preparation and Storage
  • Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: IGFBP-3
The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. ALS (Acid Labile Subunit) is a liver-derived protein that exists in a ternary complex with Insulin-like Growth Factor (IGF)-binding Protein-3 (IGFBP-3) or IGFBP-5, and either IGF-I or IGF-II. ALS increases the half-life of IGF/IGFBP complexes in circulation.
    • Long Name
      Insulin-like Growth Factor Binding Protein 3
    • Entrez Gene IDs
      3486 (Human); 16009 (Mouse);
    • Alternate Names
      acid stable subunit of the 140 K IGF complex; binding protein 29; binding protein 53; growth hormone-dependent binding protein; IBP-3; IBP3BP-53; IGF-binding protein 3; IGFBP3; IGFBP-3; insulin-like growth factor binding protein 3; insulin-like growth factor-binding protein 3;
    Related Research Areas
    Assay Procedure
    Refer to the product for complete assay procedure.

    The conjugate must remain at 2-8 °C until use. Bring all other reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
    1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
    2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

    3. 100 µL Assay Diluent
    4.   Add 100 µL of Assay Diluent to each well.

    5. 100 µL Standard, Control, or Sample
    6.   Add 100 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at 2-8 °C for 2 hours.
    7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

    8. 200 µL cold Conjugate
    9.   Add 200 µL of cold Conjugate to each well. Cover with a new plate sealer, and incubate at 2-8 °C for 2 hours.
    10.   Aspirate and wash 4 times.

    11. 200 µL Substrate Solution
    12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.

    13. 50 µL Stop Solution
    14. Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

    R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

    Showing Results 1 - 10 of 16
    Filter your results:

    Sample Type
    1. Effects of exercise and milk fat globule membrane (MFGM) supplementation on body composition, physical function, and hematological parameters in community-dwelling frail Japanese women: a randomized double blind, placebo-controlled, follow-up trial.
      Authors: Kim H, Suzuki T, Kim M, Kojima N, Ota N, Shimotoyodome A, Hase T, Hosoi E, Yoshida H
      PLoS ONE, 2015;10(2):e0116256.
      Species: Human
      Sample Type: Serum
    2. Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
      Authors: Choi Y, Park G, Rho J, Kim S, So G, Kim H, Choi C, Lee J
      PLoS ONE, 2013;8(12):e81393.
      Species: Human
      Sample Type: Cell Culture Supernates
    3. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
      Authors: Imamura, Yusuke, Sakamoto, Shinichi, Endo, Takumi, Utsumi, Takanobu, Fuse, Miki, Suyama, Takahito, Kawamura, Koji, Imamoto, Takashi, Yano, Kojiro, Uzawa, Katsuhir, Nihei, Naoki, Suzuki, Hiroyosh, Mizokami, Atsushi, Ueda, Takeshi, Seki, Naohiko, Tanzawa, Hideki, Ichikawa, Tomohiko
      PLoS ONE, 2012;7(8):e42456.
      Species: Human
      Sample Type: Cell Culture Supernates
    4. Plasminogen activator inhibitor 1--insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence.
      Authors: Elzi, David J, Lai, Yanlai, Song, Meihua, Hakala, Kevin, Weintraub, Susan T, Shiio, Yuzuru
      Proc Natl Acad Sci U S A, 2012;109(30):12052-7.
      Species: Human
      Sample Type: Cell Culture Supernates
    5. Maternal and fetal placental growth hormone and IGF axis in type 1 diabetic pregnancy.
      Authors: Higgins MF, Russell NE, Crossey PA, Nyhan KC, Brazil DP, McAuliffe FM
      PLoS ONE, 2012;7(2):e29164.
      Species: Human
      Sample Type: Plasma
    6. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial.
      Eur J Clin Nutr, 2012;66(8):878-84.
      Species: Human
      Sample Type: Serum
    7. Benefits of recombinant adeno-associated virus (rAAV)-mediated insulinlike growth factor I (IGF-I) overexpression for the long-term reconstruction of human osteoarthritic cartilage by modulation of the IGF-I axis.
      Authors: Weimer A, Madry H, Venkatesan JK
      Mol. Med., 2012;18(1):346-58.
      Species: Human
      Sample Type: Cell Culture Supernates
    8. The stature of boys is inversely correlated to the levels of their sertoli cell hormones: do the testes restrain the maturation of boys?
      Authors: Morgan K, Dennis NA, Ruffman T, Bilkey DK, McLennan IS
      PLoS ONE, 2011;6(6):e20533.
      Species: Human
      Sample Type: Serum
    9. Prognostic significance of angiogenic factors in uterine cervical cancer.
      Authors: Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S
      Anticancer Res., 2011;31(8):2589-95.
      Species: Human
      Sample Type: Serum
    10. Abnormalities in metalloproteinase pathways and IGF-I axis: a link between birth weight, hypertension, and vascular damage in childhood.
      Authors: Sesso R, Franco MC
      Am. J. Hypertens., 2010;23(1):6-11.
      Species: Human
      Sample Type: Plasma
    11. Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma.
      Authors: Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Florenes VA
      Int. J. Cancer, 2010;126(2):350-61.
      Species: Human
      Sample Type: Plasma
    12. Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting insulin-like growth factor binding protein-3, tumor cell proliferation, and angiogenic factors.
      Authors: Akhtar S, Meeran SM, Katiyar N, Katiyar SK
      Clin. Cancer Res., 2009;15(3):821-31.
      Species: Human
      Sample Type: Plasma
    13. Role of insulin-like growth factor binding protein-3 in allergic airway remodeling.
      Authors: Veraldi KL, Gibson BT, Yasuoka H, Myerburg MM, Kelly EA, Balzar S, Jarjour NN, Pilewski JM, Wenzel SE, Feghali-Bostwick CA
      Am. J. Respir. Crit. Care Med., 2009;180(7):611-7.
      Species: Human
      Sample Type: BALF
    14. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome.
      Authors: Schoyer KD, Liu HC, Witkin S, Rosenwaks Z, Spandorfer SD
      Fertil. Steril., 2007;88(1):139-44.
      Species: Human
      Sample Type: Serum
    15. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
      Authors: Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A
      Clin. Cancer Res., 2007;13(3):1000-9.
      Species: Human
      Sample Type: Plasma
    16. Insulin-like growth factor-II (IGF-II), IGF-binding protein-3 (IGFBP-3), and IGFBP-4 in follicular fluid are associated with oocyte maturation and embryo development.
      Authors: Wang TH, Chang CL, Wu HM, Chiu YM, Chen CK, Wang HS
      Fertil. Steril., 2006;86(5):1392-401.
      Species: Human
      Sample Type: Follicular Fluid
    Expand to show all
    ELISA Controls
    Description Application Cat# Citations Images  

    Quantikine Immunoassay Control Group 8

    Ctrl QC23
    View Sizes & Prices
    Catalog# Size Price Stock Quantity
    Loading Information....
    Supplemental ELISA Products
    Description Application Cat# Citations Images  

    Quantikine Wash Buffer 1

    ELISA WA126 5
    View Sizes & Prices
    Catalog# Size Price Stock Quantity
    Loading Information....

    Have you used Human IGFBP-3 Quantikine ELISA Kit?

    Submit a review and receive a $25 amazon gift card if you include an image - $10 Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

    Order Details

    Contact Information

    Certificate of Analysis Lookup

    The document you requested is not available online. Please enter the Catalog Number and Lot Number below to have a document emailed to you at the address provided

    Certificate of Analysis Lookup

    Research Areas of Interest
    R&D Systems Guarantee

    Customers Who Viewed
    This Item Also Viewed


    Customer Information